Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 2/20 | 0.46 |
| ▸ | ACLY | P53396 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 4/20 | 0.43 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.42 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 3/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.35 |
| ▸ | AHR | P35869 | 1/20 | 0.35 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15516386 | 0.92 | NOTUM (0.41) | NOTUMACLYHTR2CPTPN5RAPGEF4 | |
| SCHEMBL15562144 | 0.85 | NOTUM (0.53) | NOTUMHTR2CPTPN5CNR1DRD2 | |
| SCHEMBL15907146 | 0.80 | GABRA1 (0.32) | NOTUMACLYGABRB2 | |
| SCHEMBL1662047 | 0.80 | TSHR (0.41) | DRD2GRM2 | |
| SCHEMBL23639043 | 0.78 | SCN9A (0.38) | NOTUMACLYHTR2CPTPN5RAPGEF4 | |
| SCHEMBL21312030 | 0.78 | SCN9A (0.38) | NOTUMACLYHTR2CPTPN5RAPGEF4 | |
| SCHEMBL15561902 | 0.78 | TSHR (0.47) | DRD2GRM2 | |
| SCHEMBL16959085 | 0.78 | NOTUM (0.47) | NOTUMHTR2CPTPN5CNR1DRD2 | |
| SCHEMBL28876087 | 0.78 | NOTUM (0.47) | NOTUMHTR2CPTPN5CNR1DRD2 | |
| SCHEMBL7784381 | 0.77 | HTR1A (0.36) | NOTUMACLYHTR2CRAPGEF4FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023134629-A1 | NUCLEAR TRANSPORT REGULATOR AND USE THEREOF | 上海海雁医药科技有限公司 | 2023-07-20 | — | — | WO | disclosed |
| WO-2023134629-A1 | NUCLEAR TRANSPORT REGULATOR AND USE THEREOF | 上海海雁医药科技有限公司 | 2023-07-20 | — | — | WO | disclosed |
| EP-2887802-A2 | METHODS OF SOIL PEST CONTROL | Syngenta Participations AG (CH) | 2015-07-01 | — | — | EP | disclosed |
| WO-2014029706-A2 | METHODS OF CONTROLLING INSECTS | SYNGENTA PARTICIPATIONS AG (CH) | 2014-02-27 | — | — | WO | disclosed |
| WO-2014029710-A2 | METHODS OF SOIL PEST CONTROL | SYNGENTA PARTICIPATIONS AG (CH) | 2014-02-27 | — | — | WO | disclosed |
| WO-2014029708-A1 | METHODS OF CONTROLLING INSECTS | SYNGENTA PARTICIPATIONS AG (CH) | 2014-02-27 | — | — | WO | disclosed |
| WO-2014029707-A1 | METHODS OF CONTROLLING INSECTS | SYNGENTA PARTICIPATIONS AG (CH) | 2014-02-27 | — | — | WO | disclosed |
| WO-2014019609-A1 | METHODS OF PEST CONTROL IN SOYBEAN | SYNGENTA PARTICIPATIONS AG (CH) | 2014-02-06 | — | — | WO | disclosed |
| EP-2307394-B1 | SULPHONAMIDES AS VANILLOID RECEPTOR ANTAGONIST | AMOREPACIFIC CORP (KR) | 2012-09-26 | — | — | EP | disclosed |
| CN-102137851-A | Novel compounds as vanilloid receptor antagonists, isomers thereof or pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the same | AMOREPACIFIC CORP | 2011-07-27 | — | — | CN | disclosed |
| US-20110152318-A1 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | AMOREPACIFIC CORPORATION (KR) | 2011-06-23 | — | — | US | disclosed |
| EP-2307394-A2 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | Amorepacific Corporation (KR) | 2011-04-13 | — | — | EP | disclosed |
| WO-2010002209-A2 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | AMOREPACIFIC CORPORATION (KR) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152318-A1 | NOVEL COMPOUNDS, ISOMER THEREOF, OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF AS VANILLOID RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | TRPV1, TRPA1, TRPV2 | NOTUM 3391/4885ACLY 3397/4885HTR2C 274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.